|
|
U.S. Products
We offer a wide range of plasma-derived and recombinant therapies and pharmaceuticals for the treatment of bleeding disorders. We also provide a variety of products used in the hospital setting for critical care, for primary immunological disorders, and as a thrombolytic agent.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The products listed may not have been approved in other countries and may not be available everywhere.
» Transplant Medicine
» Coagulation
» Critical Care & Immunology
» Alpha-1
» Inhibitors
Transplant Medicine
Coagulation
Critical Care & Immunology
Immune Mediated Disorders
|
|
Privigen®Immune Globulin Intravenous (Human) 10%
Warning: Immune Globulin Intravenous (Human) (IGIV) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. See boxed warning and the PRECAUTIONS and DOSAGE AND ADMINISTRATION section of full Prescribing information for important information intended to reduce the risk of acute renal failure.
Product Site Product Details
Full Prescribing Information for Privigen.
|
|
|
Carimune® NF NanofilteredImmune Globulin Intravenous (Human)
Warning: Immune Globulin Intravenous (Human) (IGIV) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. See boxed warning and the PRECAUTIONS and DOSAGE AND ADMINISTRATION section of full Prescribing information for important information intended to reduce the risk of acute renal failure.
Product Details
Full Prescribing Information for Carimune® NF Nanofiltered
|
|
|
Hizentra®Immune Globulin Subcutaneous (Human) 20% Liquid
Product Site Product Details
Full Prescribing Information for Hizentra®
|
Rh Immunoprophylaxis
|
|
Rhophylac®Rho(D) Immune Globulin Intravenous (Human)
This warning does not apply to Rh0(D)-negative patients treated for the suppression of Rh isoimmunization.
Warning: Intravascular hemolysis leading to death has been reported in Rh0(D)-positive patients treated for immune thrombocytopenic purpura (ITP) with Rh0(D) Immune Globulin Intravenous (Human) products. Intravasular hemolysis can lead to clinically compromising anemia and multi-system organ failure, including acute respiratory distress syndrome (ARDS). Serious complications, including severe anemia, acute renal insufficiency, renal failure, and disseminated intravascular coagulation (DIC), have also been reported. Closely monitor patients treated for ITP with Rhophylac in a healthcare setting for at least 8 hours after administration. See full prescribing information for complete boxed warning.
Rhophylac Product Site
Product Details
Full Prescribing Information for Rhophylac®
|
Alpha-1
Inhibitors
|